New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Naïve Patients
IMBRUVICA effectively impacted cancerous cells while sparing non-cancerous white blood cells through one year of treatment
This release corresponds to abstract #7524
NORTH CHICAGO, Ill., June 5, 2017 -- (Healthcare Sales & Marketing Network) -- IMBR... Biopharmaceuticals, Oncology AbbVie, IMBRUVICA, ibrutinib, chronic lymphocytic leukemia
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news
More News: Cancer & Oncology | Chemotherapy | Chronic Leukemia | Chronic Lymphocytic Leukemia | Leukemia | Marketing | Pharmaceuticals